Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 1.00 |
| ▸ | FBP1 | P09467 | 3/20 | 0.61 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.61 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | GAK | O14976 | 1/20 | 0.61 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.61 |
| ▸ | ABL1 | P00519 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CDK1 | P06493 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | SRC | P12931 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | KDR | P35968 | 1/20 | 0.61 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8315445 | 0.87 | EGFR (0.77) | EGFRERBB2KDM4EMAPK1 | |
| SCHEMBL4365259 | 0.83 | EGFR (0.71) | EGFRFBP1ERBB2GAKABL1 | |
| SCHEMBL14443550 | 0.83 | EGFR (1.00) | EGFRFBP1ERBB2EPHB2KDM4E | |
| Hydrochloric Acid SCHEMBL7665624 | 0.82 | EGFR (0.70) | EGFRFBP1ERBB2GAKABL1 | |
| SCHEMBL14040968 | 0.80 | EGFR (1.00) | EGFRFBP1 | |
| SCHEMBL7216369 | 0.79 | EGFR (1.00) | EGFRFBP1ERBB2EPHB2KDM4E | |
| SCHEMBL15070939 | 0.79 | EGFR (0.71) | EGFRFBP1ERBB2EPHB2KDM4E | |
| SCHEMBL4525877 | 0.79 | EGFR (0.71) | EGFRFBP1ERBB2GAKABL1 | |
| Hydrochloric Acid SCHEMBL6207449 | 0.78 | EGFR (0.70) | EGFRFBP1ERBB2GAKABL1 | |
| SCHEMBL4348523 | 0.76 | FBP1 (1.00) | EGFRFBP1ERBB2EPHB2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11478477-B2 | Method for treating cancer by combination of FAK/ALK/ROS1 inhibitor and EGFR inhibitor | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-10-25 | — | — | US | claimed |
| US-11390600-B2 | Crystalline forms of C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. (US) | 2022-07-19 | — | — | US | claimed |
| EP-4011376-A2 | COMBINATION OF AN ALK INHIBITOR AND AN EGFR INHIBITOR FOR TREATING CANCER | Ascentage Pharma (Suzhou) Co., Ltd. (CN) | 2022-06-15 | — | — | EP | claimed |
| US-20260000714-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN NON-HUMAN ANIMALS | BIOMED VALLEY DISCOVERIES INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-4653054-A2 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | Biomed Valley Discoveries, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| US-12433920-B2 | C. novyi for the treatment of solid tumors in non-human animals | BIOMED VALLEY DISCOVERIES, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| EP-4108248-B1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | BIOMED VALLEY DISCOVERIES INC (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-4599890-A2 | SUNITINIB FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | Kyoto University (JP) | 2025-08-13 | — | — | EP | disclosed |
| EP-4011376-B1 | COMBINATION OF AN ALK INHIBITOR AND AN EGFR INHIBITOR FOR TREATING CANCER | ASCENTAGE PHARMA SUZHOU CO LTD (CN) | 2025-04-30 | — | — | EP | disclosed |
| US-20250084059-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES INC (US) | 2025-03-13 | — | — | US | disclosed |
| US-20220324832-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-13 | — | — | US | disclosed |
| US-11439669-B2 | C. novyi for the treatment of solid tumors in humans | BIOMED VALLEY DISCOVERIES, INC. (US) | 2022-09-13 | — | — | US | disclosed |
| US-11390600-B2 | Crystalline forms of C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| EP-4011376-A2 | COMBINATION OF AN ALK INHIBITOR AND AN EGFR INHIBITOR FOR TREATING CANCER | Ascentage Pharma (Suzhou) Co., Ltd. (CN) | 2022-06-15 | — | — | EP | disclosed |
| EP-3730146-B1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | BIOMED VALLEY DISCOVERIES INC (US) | 2022-05-04 | — | — | EP | disclosed |
| EP-3039122-B1 | GENERATION OF ENDOCRINE PROGENITOR CELLS FROM HUMAN PLURIPOTENT STEM CELLS USING SMALL MOLECULES | NOVO NORDISK AS (DK) | 2019-07-17 | — | — | EP | disclosed |
| US-20180000771-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2018-01-04 | — | — | US | disclosed |
| US-20160208215-A1 | Generation of Endocrine Progenitor Cells from Human Pluripotent Stem Cells Using Small Molecules | TAKARA BIO EUROPE AB (SE) | 2016-07-21 | — | — | US | disclosed |
| US-20160208215-A1 | Generation of Endocrine Progenitor Cells from Human Pluripotent Stem Cells Using Small Molecules | TAKARA BIO EUROPE AB (SE) | 2016-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084059-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | EGFR 569/4885FBP1 875/4885ERBB2 452/4885 |
| US-20220324832-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | EGFR 569/4885FBP1 875/4885ERBB2 452/4885 |
| US-12433920-B2 | C. novyi for the treatment of solid tumors in non-human animals | MKI67, HCCS, NCF1 | EGFR 1667/4885FBP1 3446/4885ERBB2 1977/4885 |
| US-20180000771-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | WEE2, WEE1, ERBB2 | EGFR 232/4885FBP1 1661/4885ERBB2 3/4885 |
| US-20260000714-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN NON-HUMAN ANIMALS | KIT, CPA3, MKI67 | EGFR 3015/4885FBP1 4396/4885ERBB2 2467/4885 |
| US-11478477-B2 | Method for treating cancer by combination of FAK/ALK/ROS1 inhibitor and EGFR inhibitor | ROS1, ALK, PTK2 | EGFR 5/4885FBP1 1322/4885ERBB2 6/4885 |
| US-11439669-B2 | C. novyi for the treatment of solid tumors in humans | HCCS, MKI67, PBK | EGFR 1748/4885FBP1 3692/4885ERBB2 1686/4885 |
| US-11390600-B2 | Crystalline forms of C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | EGFR 569/4885FBP1 875/4885ERBB2 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.